Sumitomo Pharma Co., Ltd. DNPUF
Set alert
10.50 USD -1.41 -11.84%
At close · Oct 30
10.50 Day range 10.50
8.41 52-week range 19.20
- YTD
- -26.88%
- 1 year
- -4.46%
- Open
- 10.50
- Prev close
- 11.91
- Mkt cap
- 4.71B
- Vol
- 118
- Avg vol
- 56
- EPS
- 0.68
- P/E
- 15.44
More statistics
- Low
- 10.50
- High
- 10.50
- Earnings
- Nov 4, 2026
3M chart
Events in this range
- Jul 31, 2026Earnings: 0.2399; estimate 0.1176; surprise 104%
Signals (5)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.1248.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.1248 | — | — | — |
| Jul 31, 2026 | Jun 30, 2026 | 0.1176 | 0.2399 | +0.12 | +104.00% |
| May 13, 2026 | Mar 31, 2026 | -0.09599 | -0.01285 | +0.08 | +86.61% |
| Jan 30, 2026 | Dec 31, 2025 | -0.00555 | 0.1416 | +0.15 | +2,651.35% |
| Oct 31, 2025 | Sep 30, 2025 | 0.534 | 1.49 | +0.96 | +179.03% |
| Jul 31, 2025 | Jun 30, 2025 | 0.1368 | 0.1957 | +0.06 | +43.06% |
News
- Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia
- Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript
- Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment
Your note
Sign in to keep a note on DNPUF — it syncs with the Stock Master app.